Piribedil: Antiparkinsonian properties and potential clinical utility in dopaminergic disorders

Current Drug Therapy

Volumn 6, Issue 1, 2011, Pages 17-34

  Mittur, Aravind ^a  

^a Impax Pharmaceuticals   (United States)

Author keywords

Adrenergic antagonist; Attention; Cognitive dysfunction; Dopamine agonist; Drug repositioning; Executive functions; Parkinson's disease; Tremor

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; LISURIDE; PARDOPRUNOX; PIRIBEDIL; PLACEBO; PRAMIPEXOLE; QUINPIROLE; ROPINIROLE; TALIPEXOLE; TERGURIDE;

ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; ATTENTION DEFICIT DISORDER; COGNITION; DEPRESSION; DOPAMINERGIC ACTIVITY; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG SAFETY; DRUG STRUCTURE; HALLUCINATION; HUMAN; HYPOTENSION; MANIA; MONOTHERAPY; MOTOR PERFORMANCE; NAUSEA; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROLACTIN INHIBITION; RESTLESS LEGS SYNDROME; SCHIZOPHRENIA; SINGLE DRUG DOSE; STOMACH DISCOMFORT; VOMITING;

EID: 78650958337     PISSN: 15748855     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488511794079004     Document Type: Article

References (230)

1. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004; 363: 1783-93.
2. Weintraub D, Comella CL, Horn S. Parkinson's disease--Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment. Am J Manag Care 2008; 14: S40-8.
3. Weintraub D, Comella CL, Horn S. Parkinson's disease--Part 3: Neuropsychiatric symptoms. Am J Manag Care 2008; 14: S59-S69.
4. Weintraub D, Comella CL, Horn S. Parkinson's disease--Part 2: Treatment of motor symptoms. Am J Manag Care 2008; 14: S49-S58.
5. Goetz CG, Emre M, Dubois B. Parkinson's disease dementia: definitions, guidelines, and research perspectives in diagnosis. Ann Neurol 2008; 64: S81-S92.
6. Rosenthal E, Brennan L, Xie S, et al. Association between cognition and function in patients with Parkinson disease with and without dementia. Mov Disord 2010; 25: 1170-6.
7. Owen AM. Cognitive dysfunction in Parkinson's disease: the role of frontostriatal circuitry. Neuroscientist 2004; 10: 525-37.
8. Bronnick K, Emre M, Lane R, Tekin S, Aarsland D. Profile of cognitive impairment in dementia associated with Parkinson's disease compared with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2007; 78: 1064-68.
9. Leverenz JB, Quinn JF, Zabetian C, Zhang J, Montine KS, Montine TJ. Cognitive impairment and dementia in patients with Parkinson disease. Curr Top Med Chem 2009; 9: 903-12.
10. Maggini M, Vanacore N, Raschetti R. Cholinesterase inhibitors: drugs looking for a disease? PLoS Med 2006; 3: e140.
11. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 2002; 41: 261-309.
12. Jenner P. Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. J Neurol 2000; 247: 1143-50.
13. Brotchie JM. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord 2005; 20: 919-31.
14. Tsai RS, Tayara NE, Carrupt P, Testa B. Physicochemical properties and transport behaviour of piribedil: Considerations on its membrane-crossing potential. Int J Pharmaceut 1992; 80: 39-49.
15. Demirel M, Yazan Y, Müller RH, Kiliç F, Bozan B. Formulation and in vitro-in vivo evaluation of piribedil solid lipid micro- and nanoparticles. J Microencapsul 2001; 18: 359-71.
16. Jenner P, Taylor AR, Campbell DB. Letter: Preliminary investigation of the metabolism of piribedil (ET 495); a new central dopaminergic agonist and potential anti-parkinson agent. J Pharm Pharmacol 1973; 25: 749-50.
17. Sarati S, Caccia S. Solid-phase extraction of piribedil and its metabolites from plasma and urine without and after deconjugation, by high performance liquid chromatography. Eur J Drug Metab Phar-macokinet 1992; 17: 205-11.
18. Sarati S, Guiso G, Garattini S, Caccia S. Kinetics of piribedil and effects on dopamine metabolism: hepatic biotransformation is not a determinant of its dopaminergic action in rats. Psychopharmacology (Berl) 1991; 105: 541-45.
19. Sarati S, Guiso G, Spinelli R, Caccia S. Determination of piribedil and its basic metabolites in plasma by high-performance liquid chromatography. J Chromatogr 1991; 563: 323-32.
20. Pagliari R, Peyrin L, Crambes O. Differential regional and kinetics effects of piribedil and bromocriptine on dopamine metabolites: a brain microdialysis study in freely moving rats. J Neural Transm Gen Sect 1995; 101: 13-26.
21. Campbell DB, Jenner P, Taylor AR. Metabolism and kinetics of ET 495 (Piribedil) in man and rats. Adv Neurol 1973; 3: 199-213.
22. Pubchem Bioassay Database. http://pubchem.ncbi.nlm.nih.gov/ (Accessed April 10, 2010).
23. Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Phys 2007; 76: 391-6.
24. Raghavan N, Zhang D, Zhu M, Zeng J, Christopher L. Cyp2D6 catalyzes 5-hydroxylation of 1-(2-pyrimidinyl)-piperazine, an active metabolite of several psychoactive drugs, in human liver microsomes. Drug Metab Dispos 2005; 33: 203-8.
25. Fanelli R, Frigerio A, Garattini S. Levels of piribedil and its active metabolite (S-584) in the rat striatum. Xenobiotica 1975; 5: 595-600.
26. Caccia S, Fong MH, Guiso G. Disposition of the psychotropic drugs buspirone, MJ-13805 and piribedil, and of their common active metabolite 1-(2-pyrimidinyl)-piperazine in the rat. Xenobiotica 1985; 15: 835-44.
27. Allain H. Pharmacological properties and pharmacokinetics of piribedil - logic of its use in the treatment of Parkinson's disease. Dis Manag Health Outcomes 2001; 9: 41-8.
28. Trivastal, Summary of Product Characteristics, Serdia Pharmaceu-ticals, a division of Servier Labs, 2008.
29. Montastruc JL, Ziegler M, Rascol O, Malbezin M. A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease. Mov Disord 1999; 14: 336-41.
30. Ziegler M. Clinical evidence of the effectiveness of piribedil in Parkinson's disease. Dis Manage Health Outcomes 2001; 9: 49-58.
31. Al-Fulaij MA, Ren Y, Beinborn M, Kopin AS. Identification of amino acid determinants of dopamine 2 receptor synthetic agonist function. J Pharmacol Exp Ther 2007; 321: 298-307.
32. Millan MJ, Cussac D, Milligan G, et al. The antiparkinsonian agent, piribedil, displays antagonist properties at native rat and cloned human a2-adrenoceptors: a cellular and functional characterization. J Pharmacol Exp Ther 2001; 297: 876-87.
33. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002; 303: 791-804.
34. Newman-Tancredi A, Cussac D, Audinot V, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D2-like receptor and 1/ 2-adrenoceptor. J Pharmacol Exp Ther 2002; 303: 805-14.
35. Newman-Tancredi A, Cussac D, Quentric Y, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J Pharmacol Exp Ther 2002; 303: 815-22.
36. Cagnotto A, Parotti L, Mennini T. In vitro affinity of piribedil for dopamine D3 receptor subtypes, an autoradiographic study. Eur J Pharmacol 1996; 313: 63-7.
37. Glennon JC, Van Scharrenburg G, Ronken E, et al. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist. Synapse 2006; 60: 599-608.
38. Gobert A, Di Cara B, Cistarelli L, Millan MJ. Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetyl-cholinesterase inhibitors. J Pharmacol Exp Ther 2003; 305: 338-46.
39. Miller RJ, Iversen LL. Stimulation of a dopamine-sensitive adenyate cyclase in homogenates of rat striatum by a metabolite of piribedil (ET 495). Naunyn Schmiedebergs Arch Pharmacol 1974; 282: 213-6.
40. Costall B, Naylor RJ. Dopamine agonist and antagonist activities of piribedil (ET495) and its metabolites. Naunyn Schmiedebergs Arch Pharmacol 1974; 285: 71-81.
41. Blier O, Chaput Y, De Montigny C. Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine--II. Effects of acute administration of 1-PP and long-term administration of tandospirone on noradrenergic neurotransmission. Neuropharmacology 1991; 30: 691-701.
42. Zuideveld KP, Rusic-pavletic J, Maas HJ, Peletier LA, Van der Graaf PH, Danhof M. Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats. J Pharmacol Exp Ther 2002; 303: 1130-7.
43. Ladinsky H, Consolo S, Garattini S. Increase in striatal acetylcholine levels in vivo by piribedil a new dopamine receptor stimulant. Life Sci 1974; 14: 1251-60.
44. Garattini S, Bareggi SR, Marc V, Calderini G, Morselli PL. Effects of piribedil on noradrenaline and MOPEG-SO4 levels in the rat brain. Eur J Pharmacol 1974; 28: 214-6.
45. Consolo S, Girotti P, Russi G, Di Chiara G. Endogenous dopamine facilitates striatal in vivo acetylcholine release by acting on D1 receptors localized in the striatum. J Neurochem 1992; 59: 1555-7.
46. Acquas E, Wilson C, Fibiger HC. Nonstriatal dopamine D1 receptors regulate striatal acetylcholine release in vivo. J Pharmacol Exp Ther 1997; 281: 360-8.
47. Stoof JC, Drukarch B, De Boer P, Westerink BHC, Groenewegen HJ. Regulation of the activity of striatal cholinergic neurons by dopamine. Neuroscience 1992; 47: 755-70.
48. Day J, Fibiger HC. Dopaminergic regulation of cortical acetylcholine release: effects of dopamine receptor agonists. Neuroscience 1993; 54: 643-8.
49. Brooks JM, Sarter M, Bruno JP. D2-like receptors in nucleus accumbens negatively modulate acetylcholine release in prefrontal cortex. Neuropharmacology 2007; 53: 455-63.
50. Bertorelli R, Consolo S. D1 and D2 dopaminergic regulation of acetylcholine release from striata of freely moving rats. J Neurochem 1990; 54: 2145-8.
51. Damsma G, De Boer P, Westerink BHC, Fibiger HC. Dopaminergic regulation of striatal cholinergic interneurons: An in vivo microdialysis study. Naunyn-Schmiedeberg's Arch Pharmacol 1990; 342: 523-8.
52. Ichikawa J, Dai J, O'Laughlin IA, Fowler WL, Meltzer HY. Atypical, but not typical, antipsychotic drugs increase cortical acetylcho-line release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 2002; 26: 325-39.
53. Dourish CT. Piribedil: behavioural, neurochemical and clinical profile of a dopamine agonist. Prog Neuropsychopharmacol Biol Psychiatry 1983; 7: 3-27.
54. Hoffmann IS, Talmaciu RK, Cubeddu LX. Interactions between endogenous dopamine and dopamine agonists at release modulatory receptors: multiple effects of neuronal uptake inhibitors on transmitter release. J Pharmacol Exp Ther 1986; 238: 437-46.
55. Calzi F, Bellasio R, Guiso G, Caccia S, Tacconi MT. Effect of piribedil and its metabolite, S584, on brain lipid peroxidation in vitro and in vivo. Eur J Pharmacol 1997; 338: 185-90.
56. Jenner P. Parkinson's disease: pathological mechanisms and actions of piribedil. J Neurol 1992; 239: S2-S8.
57. Uryu K, Laurer H, McIntosh T, Praticò D, et al. Repetitive mild brain trauma accelerates A-beta deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis. J Neurosci 2002; 22: 446-54.
58. Markesbery WR, Lovell MA. Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment. Arch Neurol 2007; 64: 954-6.
59. Corrodi H, Farnebo LO, Fuxe K, Hamberger B, Ungerstedt U. ET495 and brain catecholamine mechanisms: evidence for stimulation of dopamine receptors. Eur J Pharmacol 1972; 20: 195-204.
60. Hiremagalur J, Keshavan H, Gurbani NK, Dandiya PC. Neuro-chemical effects of ET495: mechanism of action. Pharmacol Res Commun 1981; 13: 607-15.
61. Creese I. Behavioural evidence of dopamine receptor stimulation by piribedil (ET495) and its metabolite S584. Eur J Pharmacol 1974; 28: 55-8.
62. Turle-Lorenzo N, Maurin B, Puma C, et al. The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease. J Pharmacol Exp Ther 2006; 319: 914-23.
63. Smith L, De Salvia M, Jenner P, Marsden CD. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated common marmosets. Mov Disord 1996; 11: 125-35.
64. Smith LA, Tel BC, Jackson MJ, et al. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation. Mov Disord 2002; 17: 887-901.
65. Brocco M, Dekeyne A, Papp M, Millan MJ. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors. Behav Pharmacol 2006; 17: 559-72.
66. Dourish DT, Jones RS. Dopamine agonist-induced restoration of drinking in response to hypertonic saline in adipsic dopamine denervated rats. Brain Res Bull 1982; 8: 375-9.
67. Cooper SJ, Dourish CT. Sedation, stereotypy and the inhibition of drinking after administration of ET 495 in the rat. Br J Pharmacol 1979; 66: 481P.
68. McCoy CE, Douglas FL, Goldberg LI. Selective antagonism of the hypotensive effects of dopamine agonists in spontaneously hypertensive rats. Hypertension 1986; 8: 298-302.
69. Brefel-Courbon C, Thalamas C, Peyro-Saint-Paul H, Senard JM, Montastruc JL, Rascol O. 2-Adrenoceptor antagonists: a new approach to Parkinson's disease? CNS Drugs 1998; 10: 189-207
70. Millan MJ, Lejeune F, Gobert A, et al. S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine. J Pharmacol Exp Ther 2000; 295: 1206-22.
71. Ramos BP, Arnsten AF. Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol Ther 2007; 113: 523-36.
72. Knaus AE, Muthig V, Schickinger S, et al. Alpha2-adrenoceptor subtypes--unexpected functions for receptors and ligands derived from gene-targeted mouse models. Neurochem Int 2007; 51: 277-81.
73. Schlicker E, Göthert M. Interactions between the presynaptic alpha2-autoreceptor and presynaptic inhibitory heteroreceptors on noradrenergic neurones. Brain Res Bull 1998; 47: 129-32.
74. Mizuno Y. In: Parkinson's Disease; Manucher S. Ebadi, Ronald Pfeiffer, Ed. CRC Press Florida 2005; 38: pp 443-78.
75. Coull JT, Sahakian BJ, Hodges JR. The 2 antagonist idazoxan remediates certain attentional and executive dysfunction in patients with dementia of frontal type. Psychopharmacology 1996; 123: 239-49.
76. Mavridis M, Degryse AD, Lategan AJ, Marien MR, Colpaert FC. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease. Neuroscience 1991; 41: 507-23.
77. Grondin R, Hadj Tahar A, Doan VD, Ladure P, Bédard PJ. Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. Naunyn Schmiedebergs Arch Pharmacol 2000; 361: 181-6.
78. Bezard E, Brefel C, Tison F, et al. Effect of the alpha 2 adrenore-ceptor antagonist, idazoxan, on motor disabilities in MPTP-treated monkey. Prog Neuropsychopharmacol Biol Psychiatry 1999; 23: 1237-46.
79. Fox SH, Henry B, Hill MP, Peggs D, Crossman AR, Brotchie JM. Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Mov Disord 2001; 16: 642-50.
80. Buck K, Voehringer P, Ferger B. The alpha(2) adrenoceptor an-tagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats. J Neurochem 2010; 112: 444-52.
81. Savola JM, Hill M, Engstrom M, et al. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopainduced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 2003; 18: 872-83.
82. Kable JW, Murrin LC, Bylund DB. In vivo gene modification elucidates subtype-specific functions of alpha(2)-adrenergic receptors. J Pharmacol Exp Ther 2000; 293: 1-7.
83. Chopin P, Colpaert FC, Marien M. Effects of acute and subchronic administration of dexefaroxan, an alpha(2)-adrenoceptor antagonist, on memory performance in young adult and aged rodents. J Pharmacol Exp Ther 2002; 301: 187-96.
84. Manson AJ, Lakovidou E, Lees AJ. Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease. Mov Disord 2000; 15: 336-7.
85. Rascol O, Arnulf I, Peyro-Saint Paul H, et al. Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov Disord 2001; 16: 708-13.
86. th International Congress of Parkinson's Disease and Movement Disorders, 2009.
87. Fox SH, Chuang R, Brotchie JM. Serotonin and Parkinson's disease: On movement, mood, and madness. Mov Disord 2009; 24: 1255-66.
88. Halliday GM, Blumbergs PC, Cotton RGH, Blessing WW, Geffen LB. Loss of brainstem serotonin- and substance P containing neurons in Parkinson's disease. Brain Res 1990; 510: 104-7.
89. Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ. Tremor in Parkinson's disease and serotonergic dysfunction: An 11C-WAY-100635 PET study. Neurology 2003; 60: 601-5.
90. Kannari K, Yamato H, Shen H, Tomiyama M, Suda T, Matsunaga M. Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation. J Neurochem 2001; 76: 1346-53.
91. Bartoszyk GD, Van Amsterdam C, Greiner HE, Rautenberg W, Russ H, Seyfried CA. Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand: I. Neurochemical profile. J Neural Transm 2004; 111: 113-26.
92. Iravani MM, Tayarani-Binazir K, Chu WB, Jackson MJ, Jenner P. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with increased motor disability. J Pharmacol Exp Ther 2006; 319: 1225-34.
93. Bibbiani F, Oh JD, Chase TN. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 2001; 57: 1829-34.
94. Bara-Jimenez W, Bibbiani F, Morris MJ, et al. Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov Disord 2005; 20: 932-6.
95. Grégoire L, Samadi P, Graham J, Bédard PJ, Bartoszyk GD, Di Paolo T. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys. Parkinsonism Relat Disord 2009; 15: 445-52.
96. Olanow CW, Damier P, Goetz CG, et al. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol 2004; 27: 58-62.
97. Rascol O, Damier P, Goetz CG, et al. A large phase III study to evaluate the safety and efficacy of sarizotan in the treatment of l-dopa-induced-dyskinesia associated with PD: the Paddy-1 study. Mov Disord 2006; 21: S492-3.
98. Goetz CG, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord 2007; 22: 179-86.
99. Kleedorfer B, Lees AJ, Stern GM. Buspirone in the treatment of levodopa induced dyskinesias. J Neurol Neurosurg Psychiatry 1991; 54: 376-7.
100. Bonifati V, Fabrizio E, Cipriani R, Vanacore N, Meco G. Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol 1994; 17: 73-82.
101. Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 2007; 113: 296-320.
102. Rondot P, Ziegler M. Activity and acceptability of piribedil in Parkinson's disease: a multicentre study. J Neurol 1992; 239: S28- S34.
103. Ziegler M, Castro-Caldas A, Del Signore S, Rascol O. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study. Mov Disord 2003; 18: 418-25.
104. Castro-Caldas A, Delwaide P, Jost W, et al. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease. Mov Disord 2006; 21: 500-9.
105. Rascol O, Dubois B, Caldas AC, et al. Early piribedil monotherapy of Parkinson's disease: a planned seven-month report of the REGAIN study. Parkinson REGAIN Study Group. Mov Disord 2006; 21: 2110-5.
106. Suwantamee J, Nidhinandana S, Srisuwananukorn S, et al. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study. J Med Assoc Thai 2004; 87: 1293-1300.
107. Lebrun-Frenay C, Borg M. Choosing the right dopamine agonist for patients with Parkinson's disease. Curr Med Res Opin 2002; 18: 209-14.
108. Emile J, Chanelet J, Truelle JL, Bastard J. Action of piribedil in Parkinson's disease: I.V. test and oral treatment. Adv Neurol 1975; 9: 409-13.
109. Truelle JL, Chanelet J, Bastard J, Six P, Emile J. Piribedil, dopa-minergic agonist. Prolonged clinical and electrophysiological study in 60 parkinsonian patients (author's transl). Nouv Presse Med 1977; 6: 2987-90.
110. Bathien N, Koutlidis RM, Rondot P. EMG patterns in abnormal involuntary movements induced by neuroleptics. J Neurol Neurosurg Psychiatry 1984; 47: 1002-8.
111. Mentenopoulos G, Katsarou Z, Bostantjopoulou S, et al. Piribedil therapy in Parkinson's disease: use of the drug in the retard form. Clin Neuropharmacol 1989; 12: 23-8.
112. Simon N, Micallef J, Reynier JC, et al. End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmacokinetic/pharmacodynamic, randomized, double-blind study. Mov Disord 2005; 20: 803-9.
113. Benatru I, Vaugoyeau M, Azulay JP. Postural disorders in Parkinson's disease. Neurophysiol Clin 2008; 38: 459-65.
114. Evidente VG, Esteban RP, Domingo FM, et al. Piribedil as an adjunct to levodopa in advanced Parkinson's disease: the Asian experience. Parkinsonism Relat Disord 2003; 10: 117-21.
115. Callaghan N, Fitzpatrick E, O'Mahony JB. Piribedil (ET 495) in the treatment of Parkinson's disease combined with amantadine or levodopa. Acta Neurol Scand 1975; 52: 179-86.
116. Salazar Tortolero G, Wix Ramos R, Salazar Aladren P, et al. The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up. Rev Neurol 2004; 38: 715-9.
117. Bonnet AM, Loria Y, Saint-Hilaire MH, Lhermitte F, Agid Y. Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions? Neurology 1987; 37: 1539-42.
118. Yogev-Seligmann G, Hausdorff JM, Giladi N. The role of executive function and attention in gait. Mov Disord 2008; 23: 329-42.
119. Lees A, Castro-Caldas A, Dubois B, et al. Two-year results of the REGAIN study, a placebo-controlled trial with the non-ergot dopamine agonist piribedil as early treatment of Parkinson's disease. Eur J Neurol 2005; 12: 11-36.
120. Tan EK, Ratnagopal P, Han SY, Wong MC. Piribedil and bromocriptine in Parkinson's disease: a single-blind crossover study. Acta Neurol Scand 2003; 107: 202-6.
121. Rascol O, Azulay JP, Blin O, et al. Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study. Mov Disord 2010; F25: 368-76.
122. Rolland H, Wuthrich P. Nasal pharmaceutical composition of piribedil. US Patent Publication #US2006/0204449 A1, September 14, 2006.
123. Blanchet PJ, Konitsiotis S, Chase TN. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. J Pharmacol Exp Ther 1997; 283: 794-9.
124. Sokoloff P, Diaz J, Le Foll B, et al. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 2006; 5: 25-43.
125. Boileau I, Guttman M, Rusjan P, et al. Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drugnaive Parkinson's disease. Brain 2009; 132: 1366-75.
126. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990; 347: 146-51.
127. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005; 128: 1314-22.
128. Waters N, Svensson K, Haadsma-Svensson Smith MW, Carlsson A. The dopamine DS-receptor: a postsynaptic receptor inhibitory on rat locomotor activity. J Neural Transm 1993; 94: 11-9.
129. Gobert A, Rivet JM, Audinot V, et al. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and silent D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J Pharmacol Exp Ther 1995; 275: 899-913.
130. Pritchard LM, Newman AH, McNamara RK, et al. The dopamine D3 receptor antagonist NGB 2904 increases spontaneous and amphetamine-stimulated locomotion. Pharmacol Biochem Behav 2007; 86: 718-26.
131. Kvernmo T, Houben J, Sylte I. Receptor-binding and pharmacoki-netic properties of dopaminergic agonists. Curr Top Med Chem 2008; 8: 1049-67.
132. Carey RJ. Differential effects of limbic versus striatal dopamine loss on motoric function. Behav Brain Res 1983; 7: 283-96.
133. Bezard E, erry S, Mach U, et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 2003; 9: 762-7.
134. Van Kampen JM, Eckman CB. Dopamine D3 receptor agonist delivery to a model of parkinson's disease restores the nigrostriatal pathway and improves locomotor behavior. J Neurosci 2006; 26: 7272-80.
135. Maggio R, Aloisi G, Silvano E, Rossi M, Millan MJ. Heterodi-merization of dopamine receptors: new insights into functional and therapeutic significance. Parkinsonism Relat Disord 2009; 15: S2-7.
136. Seeman P, Corbett R, Van Tol HH. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology 1997; 16: 93-110.
137. Jenner P. Pharmacology of dopamine agonists in the treatment of Parkinson's disease. Neurology 2002; 58: S1-8.
138. Rowe JB, Hughes L, Ghosh BC, et al. Parkinson's disease and dopaminergic therapy--differential effects on movement, reward and cognition. Brain 2008; 131: 2094-105.
139. Calabrese EJ. Dopamine: biphasic dose responses. Crit Rev Toxicol 2001; 31: 563-83.
140. Monte-Silva K, Kuo MF, Thirugnanasambandam N, Liebetanz D, Paulus W, Nitsche MA. Dose-dependent inverted U-shaped effect of dopamine (D2-like) receptor activation on focal and nonfocal plasticity in humans. J Neurosci 2009; 29: 6124-31.
141. Bradbury AJ, Cannon JG, Costall B, et al. A comparison of dopamine agonist action to inhibit locomotor activity and to induce stereotyped behaviour in the mouse. Eur J Pharmacol 1984; 105: 33-47.
142. Rinne UK, Laihinen A, Rinne JO, Nagren K, Bergman J, Ruotsalainen U. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov Disord 1990; 5: 55-9.
143. Tamminga CA, Carlsson A. Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Targets CNS Neurol Disord 2002; 1: 141-7.
144. Stahl SM. In: Depression and Bipolar Disorder. Stahl's Essential Psychopharmacology. Stephen M. Stahl, Ed. Cambridge University Press NY 2008; pp 110.
145. Stahl SM. Do Dopamine Partial Agonists Have Partial Efficacy as Antipsychotics? CNS Spectr 2008; 13: 279-82.
146. Kehne JH, Andree TH, Heinrich JN. D2 receptor partial agonists: treatment of CNS disorders of dopamine function. Curr Top Med Chem 2008; 8: 1068-88.
147. Friedman JH Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000; 15: 201-11.
148. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22: 1689-707.
149. Castner SA, Goldman-Rakic PS, Williams GV. Animal models of working memory: Insights for targeting cognitive dysfunction in schizophrenia. Psychopharmacology (Berl) 2004; 174: 111-25.
150. Croxson PL, Johansen-Berg H, Behrens TE, et al. Quantitative investigation of connections of the prefrontal cortex in the human and macaque using probabilistic diffusion tractography. J Neurosci 2005; 25: 8854-66.
151. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol 2002; 67: 53-83.
152. Robbins TW, Roberts AC. Differential regulation of fronto-executive function by the monoamines and acetylcholine. Cereb Cortex 2007; 17: i151-60.
153. Robbins TW, Arnsten AFT. The Neuropsychopharmacology of Fronto-executive function: Monoaminergic modulation. Annu Rev Neurosci 2009; 32: 267-87.
154. Phillips AG, Ahn S, Floresco SB. Magnitude of dopamine release in medial prefrontal cortex predicts accuracy of memory on a delayed response task. J Neurosci 2004; 24: 547-53.
155. Castner SA, Goldman-Rakic PS. Enhancement of working memory in aged monkeys by a sensitizing regimen of dopamine D1 receptor stimulation. J Neurosci 2004; 24: 1446-50.
156. Volkow ND, Logan J, Fowler JS, et al. Association between age-related decline in brain dopamine activity and impairment in frontal and cingulate metabolism. Am J Psychiatry 2000; 157: 75-80.
157. Cools R, Stefanova E, Barker RA, Robbins TW, Owen AM. Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain 2002; 125: 584-94.
158. Arnsten AF. Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs 2009; 23: 33-41.
159. Meador-Woodruff JH, Haroutunian V, Powchik P, Davidson M, Davis KL, Watson SJ. Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia. Arch Gen Psychiatry 1997; 54: 1089-95.
160. Frank MJ, O'Reilly RC. A mechanistic account of striatal dopamine function in human cognition: psychopharmacological studies with cabergoline and haloperidol. Behav Neurosci 2006; 120: 497-517.
161. Frank MJ, Santamaria A, O'Reilly RC, Willcutt E. Testing computational models of dopamine and noradrenaline dysfunction in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2007; 32: 1583-99.
162. Stahl SM. Mechanism of action of alpha 2A-adrenergic agonists in attention-deficit/hyperactivity disorder with or without oppositional symptoms. J Clin Psychiatry 2010; 71: 223-4.
163. Camacho F, Smith CP, Vargas HM, Winslow JT. Alpha 2-adrenoceptor antagonists potentiate acetylcholinesterase inhibitor effects on passive avoidance learning in the rat. Psychopharmacology (Berl) 1996; 124: 347-54.
164. Middleton HC, Sharma A, Agouzoul D, Sahakian BJ, Robbins TW. Idazoxan potentiates rather than antagonizes some of the cognitive effects of clonidine. Psychopharmacology (Berl) 1999; 145: 401-11.
165. Mehta MA, Sahakian BJ, McKenna PJ, Robbins TW. Systemic sulpiride in young adult volunteers simulates the profile of cognitive deficits in Parkinson's disease. Psychopharmacology (Berl) 1999; 146: 162-74.
166. Arnsten AF, Cai JX, Steere JC, Goldman-Rakic PS. Dopamine D2 receptor mechanisms contribute to age-related cognitive decline: the effects of quinpirole on memory and motor performance in monkeys. J Neurosci 1995; 15: 3429-39.
167. Hall H, Sedvall G, Magnusson O, Kopp J, Halldin C, Farde L. Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology 1994; 11: 245-56.
168. Dodds CM, Clark L, Dove A, et al. The dopamine D2 receptor antagonist sulpiride modulates striatal BOLD signal during the manipulation of information in working memory. Psychopharmacology (Berl) 2009; 207: 35-45.
169. Kulisevsky J, García-Sánchez C, Berthier ML, et al Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients. Mov Disord 2000; 15: 613-26.
170. Schuck S, Bentue-Ferrer D, Kleinermans D, R et al. Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers. Fundam Clin Pharmacol 2002; 16: 57-65.
171. Costa A, Peppe A, Dell'Agnello G, et al. Dopaminergic modulation of visual-spatial working memory in Parkinson's disease. Dement Geriatr Cogn Disord 2003; 15: 55-66.
172. Kimberg DY, D'Esposito M. Cognitive effects of the dopamine receptor agonist pergolide. Neuropsychologia 2003; 41: 1020-7.
173. Rektorová I. Effects of dopamine agonists on neuropsychiatric symptoms of Parkinson's disease. Neurodegener Dis 2010; 7: 206-9.
174. Sharma T, Anand R, Stocchi F, Borgohain R, Rossetti, S. Cognitive effects of safinamide in early Parkinson's disease (PD) patients. #770, 11th International Congress of the Movement Disorders Society, 2007.
175. Hamidovic A, Kang UJ, de Wit H. Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers. J Clin Psychopharmacol 2008; 28: 45-51.
176. Pascual-Sedano B, Kulisevsky J, Barbanoj M, et al. Levodopa and executive performance in Parkinson's disease: a randomized study. J Int Neuropsychol Soc 2008; 14: 832-41.
177. Schellekens AF, Grootens KP, Neef C, et al. Effect of apomorphine on cognitive performance and sensorimotor gating in humans. Psychopharmacology (Berl) 2010; 207: 559-69.
178. Lange KW, Robbins TW, Marsden CD, James M, Owen AM, Paul GM. L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology (Berl) 1992; 107: 394-404.
179. Relja M, Klepac N. A dopamine agonist, pramipexole, and cognitive functions in Parkinson's disease. J Neurol Sci 2006; 248:251-4.
180. Rektorová I, Rektor I, Bares M, et al. Cognitive performance in people with Parkinson's disease and mild or moderate depression: effects of dopamine agonists in an add-on to L-dopa therapy. Eur J Neurol 2005; 12: 9-15.
181. Costa A, Peppe A, Dell'Agnello G, Caltagirone C, Carlesimo GA. Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory. Neuropsychologia 2009; 47: 1374-81.
182. Brusa L, Bassi A, Stefani A, Pierantozzi M, et al. Pramipexole in comparison to l-dopa: a neuropsychological study. J Neural Transm 2003; 110: 373-80.
183. Brusa L, Tiraboschi P, Koch G, et al. Pergolide effect on cognitive functions in early-mild Parkinson's disease. J Neural Transm 2005; 112: 231-7.
184. Muller U, von Cramon DY, Pollmann S. D1- versus D2-receptor modulation of visuospatial working memory in humans. J Neurosci 1998; 18: 2720-8.
185. Luciana M, Depue RA, Arbisi P, Leon A. Facilitation of working memory in humans by a D2 dopamine receptor agonist. J Cog Neurosci 1992; 4: 58-68.
186. Gibbs SE, D'Esposito M. Individual capacity differences predict working memory performance and prefrontal activity following dopamine receptor stimulation. Cogn Affect Behav Neurosci 2005; 5: 212-21.
187. McDowell S, Whyte J, D'Esposito M. Differential effect of a dopaminergic agonist on prefrontal function in traumatic brain injury patients. Brain 1998; 121: 1155-64.
188. Ruzicka E, Roth J, Spacková N, Mecír P, Jech R. Apomorphine induced cognitive changes in Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57: 998-1001.
189. Alegret M, Valldeoriola F, Martí M, et al. Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease. Mov Disord 2004; 19: 1463-9.
190. Servan-Schreiber D, Carter CS, Bruno RM, et al. Dopamine and the mechanisms of cognition:Part II. D-amphetamine effects in human subjects performing a selective attention task. Biol Psychiatry 1998; 43: 723-9.
191. Marighetto A, Valerio S, Philippin J, et al. Comparative effects of the dopaminergic agonists piribedil and bromocriptine in three different memory paradigms in rodents. J Psychopharmacol 2008; 22: 511-21.
192. Ollat H. Dopaminergic insufficiency reflecting cerebral ageing: value of a dopaminergic agonist, piribedil. J Neurol 1992; 239: S13-6.
193. Bäckman L, Lindenberger U, Li SC, Nyberg L. Linking cognitive aging to alterations in dopamine neurotransmitter functioning: recent data and future avenues. Neurosci Biobehav Rev 2010; 34: 670-7.
194. Volkow ND, Gur RC, Wang GJ, et al. Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am J Psychiatry 1998; 155: 344-9.
195. Peretti CS, Gierski F, Harrois S. Cognitive skill learning in healthy older adults after 2 months of double-blind treatment with piribedil. Psychopharmacology (Berl) 2004; 176: 175-81.
196. Nagaraja D, Jayashree S. Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Am J Psychiatry 2001; 158: 1517-19.
197. Guell A, Geraud G, Jauzac PH, Victor G. Ame-Bes MC. Effects of a dopaminergic agonist (piribedil) on cerebral blood flow in man. J Cereb Blood Flow Metab 1982; 2: 255-7.
198. Bes A, Guell A, Fabe N, Arne-Bes MC, Geraud G. Effects of do-paminergic agonists (piribedil and bromocriptine) on cerebral blood flow in parkinsonism. J Cereb Blood Flow Metab 1983; 3: S490-1.
199. Geraud G, Ame-Bes MC, Guell A, Bes A. Reversibility of hemodynamic hypofrontality in schizophrenia. J Cereb Blood Flow Metab 1987; 7: 9-12.
200. Scholing WE, Clausen HD. Psychological studies of a long-term treatment of the neurovascular syndrom with Trivastal (author's tranls). Med Klin 1975; 70: 1522-7.
201. Peran P, Cesaro P, Aguilar M, Merello M, Bodjarian N, Dubois B. Piribedil effects on parkinsonian cognitive dysfunction compared to bromocriptine in early combination with L-dopa: The Parkinson-Control Study. Eur J Neurol 2004; 11: 286 (P2406).
202. Desitin Arzneimittel GmbH, ClinTrials.gov ID NCT01007864, http://clinicaltrials.gov/ct2/show/NCT01007864?term=piribedil&rank=3 (Accessed July 28, 2010)
203. Tadori Y, Forbes RA, McQuade RD, Kikuchi T. Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. Eur J Pharmacol 2008; 597: 27-33
204. Garcia-Sevilla JA, Escriba PV, Ozaita A, et al.Up-regulation of immunolabeled 2a-adrenoceptors, Gi coupling proteins and regulatory receptor kinases in the prefrontal cortex of depressed suicides. J Neurochem 1999; 72: 282-91.
205. Klimek V, Rajkowska G, Luker SN, et al. Brain noradrenergic receptors in major depression and schizophrenia. Neuropsycho- pharmacology 1999; 21: 69-81.
206. Zhang HT, Whisler LR, Huang Y, Xiang Y, O'Donnell JM. Postsynaptic alpha-2 adrenergic receptors are critical for the antidepres-sant-like effects of desipramine on behavior. Neuropsychopharmacology 2009; 34: 1067-77.
207. Heninger GR, Charney DS, Price LH. Noradrenergic and serotonergic receptor system function in panic disorder and depression. Acta Psychiatr Scand Suppl 1988; 341: 138-50.
208. Blier P. The pharmacology of putative early-onset antidepressant strategies. Eur Neuropsychopharm 2003; 13: 57-66.
209. Yanpallewar SU, Fernandes K, Marathe SV, et al. Alpha2-adrenoceptor blockade accelerates the neurogenic, neurotrophic, and behavioral effects of chronic antidepressant treatment. J Neurosci 2010; 30: 1096-109.
210. Litman RE, Su TP, Potter WZ, Hong WW, Pickar D. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. Br J Psychiatry 1996; 168: 571-9.
211. Angrist B, Gershon S. Clinical response to several dopamine agonists in schizophrenic and nonschizophrenic subjects. Adv Bio chem Psychopharmacol 1977; 16: 677-80.
212. Post RM, Gerner RH, Carman JS, et al. Effects of a dopamine agonist piribedil in depressed patients:relationship of pretreatment homovanillic acid to antidepressant response. Arch Gen Psychiatry 1978; 35: 609-15.
213. Angrist B, Thompson H, Shopsin B, Gershon S. Clinical studies with dopamine-receptor stimulants. Psychopharmacologia 1975; 44: 273-80.
214. Post RM, Emerson DC, Silberman K. Amphetamine and piribedil in affective illness. Psychopharmacol Bull 1980; 16: 57-9.
215. Shopsin B, Gershon S. Dopamine receptor stimulation in the treatment of depression: Piribedil (ET 495). Neuropsychobiology 1978; 4: 1-14.
216. Reus VI, Lake CR, Post RM. Effect of piribedil (ET 495) on plasma norepinephrine: relationship to antidepressant response. Psychopharmacol Commun 1980; 4: 207-13.
217. Bersani G, Pesaresi L, Orlandi V, Gherardelli S, Pancheri P. Atypical antipsychotics and polydipsia: a cause or a treatment? Hum Psychopharmacol 2007; 22: 103-7.
218. Trenkwalder C, Paulus W. Restless legs syndrome: pathophysiology, clinical presentation and management. Nat Rev Neurol 2010; 6: 337-46.
219. Paulus W, Trenkwalder C. Less is more: pathophysiology of do-paminergic-therapy-related augmentation in restless legs syndrome.Lancet Neurol 2006; 5: 878-86.
220. Evidente VG. Piribedil for restless legs syndrome: a pilot study. Mov Disord 2001; 16: 579-81.
221. Engel J, Granerus AK, Svanborg A. Piribedil in Parkinson's syndrome: a clinical study. Eur J Clin Pharmacol 1975; 8: 223-6.
222. Hutchinson M, Fazzini E. Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry 1996; 61: 324-5.
223. Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006; 21: 1899-907.
224. Schäfer D, Greulich W. Effects of parkinsonian medication on sleep. J Neurol 2000; 247: IV/24-7.
225. Homann CN, Wenzel K, Suppan K, et al. Sleep attacks in patients taking dopamine agonists: review. BMJ 2002; 324: 1483-7.
226. Ferreira JJ, Desboeuf K, Galitzky M, et al. Sleep disruption, day-time somnolence and 'sleep attacks' in Parkinson's disease: a clinical survey in PD patients and age-matched healthy volunteers. Eur J Neurol 2006; 13: 209-14.
227. Schachter M. In: Side Effects of Drugs Annual 28. Jeffrey K. Aronson, Ed. Elsevier B.V. Amsterdam 2005; pp163.
228. European Medicines Agency (EMEA). Dopaminergic substances and sudden sleep onset. CPMP position statement, CPMP/578/02Rev 1, 2002.
229. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007; 356: 39-46.
230. Jain C, Waters CH. Controversies of Dopamine Agonists: Somno-lence, Cardiac Valvulopathy and Repetitive Behaviors. Curr Drug Ther 2007; 2: 17-20.